Skip to main content
. 2019 Mar 30;9(3):e024111. doi: 10.1136/bmjopen-2018-024111

Table 4.

Conclusions, the number of MAs, average CC/CO/CS studies and patients and average AMSTAR score about the association between SCH and other diseases

Conclusions No of included MAs Average CC/CO/CS studies included Average patients included Average AMSTAR score
Plasma homocysteine levels were not found to be significantly higher in patients with SCH58 1 3/5/0 926 10.00
SCH is not significantly associated with fractures30 52 54 3 0/8/0 128 667 9.7
SCH was associated with increased risk of any location of fractures, hip fractures and forearm fractures60 1 0/13/0 62 490 10
No evidence which could prove a definite association between SCH and the risk of fracture79 1 0/6/0 289 575 7
Serum TC, LDL-C and TG levels were significantly increased in patients with SCH compared with euthyroidism individuals. No significant difference was observed for serum HDL-C36 42 2 5/0/7 22 767 9.00
SCH is associated with a significant decrease in fasting plasma glucose36 1 3/0/1 3507 9.00
SCH is not significantly associated with BMI36 1 7/0/1 3971 9.00
SCH was associated with a significant increase in SBP31 36 56 3 1.7/2/7 23 485 8.00
SCH was associated with a significant increase in DBP31 1 0/0/6 17 323 8.00
SCH is not significantly associated with increased DBP36 56 2 1.7/1.7/5 25 810 8.00
SCH is associated with a significant increase in C-IMT36 59 66 75 4 6.75/3.5/0.5 2420 8.75
SCH has a significant association with arterial wall thickening and stiffening and endothelial dysfunction and increased risk of cardiovascular events59 1 27/0/0 1931 9
SCH is significantly associated with an increased risk for CHD50 63 2 0/6.5/1 8528 7.5
SCH is not significantly associated with an increased risk for CHD28 44 77 0/9.3/0 18 525 7.30
SCH is significantly associated with an increased risk for cardiovascular mortality50 63 2 0/3.5/0.5 6525 7.5
SCH is not significantly associated with an increased risk for cardiovascular mortality28 44 2 0/10/0 33 444 8.00
SCH is not significantly associated with an increased risk for all-cause mortality28 44 50 3 0/6.3/0.3 24 853 7.00
SCH is significantly associated with MetS as defined by the IDF Criteria55 1 0/0/2 7258 10.00
SCH is not significantly associated with MetS as defined by the NCEP-ATP III Criteria34 55 2 2/0/5 24 717 10.00
SCH is not significantly associated with MetS as defined by the Chinese Criteria55 1 0/0/1 1399 10.00
SCH is not significantly associated with MetS as defined by the Japanese Criteria55 1 0/0/2 10 350 10.00
SCH is not significantly associated with cognitive impairment29 45 47 3 0/8.3/4.3 16 833 9.33
SCH patients had significantly worse parameters of left ventricular diastolic function than euthyroid subjects aged <60 years33 1 0/0/14 675 7.00
SCH is significantly associated with a risk factor for gestational diabetes37 1 0/6/0 63 567 7
SCH can significantly increase the risk of diabetic retinopathy in T2DM patients38 53 2 0/8.5/0.5 4101 9.5
SCH can significantly increase the risk of diabetic nephropathy in T2DM patients38 62 2 6/0/1.5 2653 8.5
SCH can significantly increase the risk of diabetic peripheral neuropathy in T2DM patients38 1 3/0/0 1710 10
SCH can significantly increase the risk of peripheral arterial disease in T2DM patients38 1 4/0/0 801 10
SCH is not significantly associated with coronary heart disease in T2DM patients38 1 7/0/0 1896 10
SCH is a significant risk factor of chronic kidney disease in T2DM patients78 1 4/0/2 38 284 6
No significant correlation was found between SCH and stroke32 1 0/5/0 10 118 10
SCH does not influence the hormonal profile of women with polycystic ovary syndrome. But it results in mild metabolic abnormalities in a short-term setting66 1 0/12/0 2341 10
Maternal SCH is not significantly associated with the occurrence of preterm birth48 1 0/10/0 48 684 8
Maternal SCH significantly increases the risk of preterm birth41 59 64 71 4 0/14.1/0 110 951 9.3
Maternal SCH is significantly associated with the risk for intrauterine growth restriction51 64 2 0/5/0 12 558 8.5
Maternal SCH has a significant adverse affect on the intelligence of offspring35 46 76 3 1/0/37 303 360 8.3
SCH patients have a higher prevalence of miscarriage67 1 0/3/0 6036 9
Children of women with SCH were found have a significant lower mean motor scores than those of euthyroidism35 1 0/1/0 160 10
No significant association was found between NAFLD and SCH72 1 0/1/4 26 454 10

AMSTAR, Assessment of Multiple Systematic Reviews; BMI, body mass index; CC/CO/CS, case–control/cohort/cross-sectional; CHD, coronary heart disease; C-IMT, carotid intima-media thickness; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; IDF, International Diabetes Federation; LDL-C, low-density lipoprotein cholesterol; MAs, meta-analyses; MetS, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; NCEP-ATP III, National Cholesterol Education Programme’s Adult Treatment Panel III; SBP, systolic blood pressure; SCH, subclinical hypothyroidism; TC, total cholesterol; TG, total triglyceride; T2DM, type 2 diabetes mellitus.